Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$26,624 Mln
Revenue (TTM)
$2,306 Mln
Net Profit (TTM)
$-208 Mln
ROE
-0.1 %
ROCE
-12.6 %
P/E Ratio
--
P/B Ratio
15.5
Industry P/E
--
EV/EBITDA
-26.8
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$12.5
EPS
$-1.5
Face value
--
Shares outstanding
141,731,250
CFO
$-1,528.27 Mln
EBITDA
$-2,147.13 Mln
Net Profit
$-2,244.55 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Natera (NTRA)
| -13.7 | -6.4 | -12.3 | 32.5 | 51.7 | 13.3 | 36.6 |
|
BSE Sensex*
| -12.4 | -11.4 | -12.2 | -1.5 | 8.6 | 8.6 | 11.5 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Natera (NTRA)
| 44.7 | 150.8 | 55.9 | -57.0 | -6.2 | 195.4 | 141.3 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Natera (NTRA)
|
197.8 | 26,624.2 | 2,306.1 | -208.2 | -11.2 | -14.3 | -- | 15.5 |
| 73.0 | 96,853.4 | 402,067.0 | 1,768.0 | 1.3 | 2.3 | 54.8 | 1.3 | |
| 99.7 | 10,098.8 | 5,935.2 | 566.2 | 18.1 | 25.1 | 18.1 | 4.1 | |
| 70.7 | 2,278.1 | 427.5 | -21.0 | -4.4 | -7.6 | -- | 7.4 | |
| 502.1 | 119,183.9 | 75,600.0 | 6,784.0 | 16.0 | -159.1 | 18.8 | 293.4 | |
| 265.8 | 21,869.0 | 13,951.7 | 876.5 | 9.5 | 10.5 | 25.2 | 2.5 | |
| 195.2 | 22,215.1 | 11,035.0 | 992.0 | 13.2 | 14.2 | 22.8 | 3.1 | |
| 203.2 | 20,005.3 | 21,310.0 | 1,407.0 | 16.9 | 33.5 | 14.7 | 4.6 | |
| 205.0 | 12,186.8 | 5,057.8 | 344.0 | 9.2 | 16.9 | 36 | 5.5 | |
| 189.6 | 11,754.3 | 17,364.8 | 1,488.8 | 12.2 | 21.4 | 8.3 | 1.6 |
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of... treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas. Read more
Co-Founder & Executive Chairman
Dr. Matthew Rabinowitz Ph.D.
Co-Founder & Executive Chairman
Dr. Matthew Rabinowitz Ph.D.
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Natera Inc (NTRA) is $197.79 (NASDAQ) as of 18-Mar-2026 16:00 EDT. Natera Inc (NTRA) has given a return of 51.72% in the last 3 years.
Since, TTM earnings of Natera Inc (NTRA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-150.47
|
18.29
|
|
2024
|
-103.68
|
16.52
|
|
2023
|
-17.19
|
9.76
|
|
2022
|
-7.22
|
5.60
|
|
2021
|
-18.32
|
13.23
|
The 52-week high and low of Natera Inc (NTRA) are Rs 256.36 and Rs 125.38 as of 19-Mar-2026.
Natera Inc (NTRA) has a market capitalisation of $ 26,624 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Natera Inc (NTRA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.59
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.